MedTrace Logo

Post-operative Adjuvant Therapy w/wo GammaTile + Systemic Therapy

NCT05900908 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2025-04-10

No results posted yet for this study

Summary

To compare surgical tumor removal and GammaTile therapy followed by adjuvant systemic therapy (bevacizumab or lomustine) to surgical tumor removal followed by adjuvant systemic therapy (bevacizumab or lomustine) without GammaTile therapy.

Conditions

Interventions

DEVICE

Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)

GammaTiles are a permanently implanted radiation device consisting of Cs-131 seeds positioned within a collagen tile

RADIATION

Stereotactic Radiation Therapy

External Beam Radiation Therapy

Sponsors & Collaborators

  • GT Medical Technologies, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-31
Primary Completion
2026-06-30
Completion
2028-06-30
FDA Device
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05900908 on ClinicalTrials.gov